{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:15:17Z","timestamp":1778944517395,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jcyt.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:56:48Z","timestamp":1751381808000},"page":"1190-1198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice"],"prefix":"10.1016","volume":"27","author":[{"given":"Xiaomeng","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McAlister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Kinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5329-0708","authenticated-orcid":false,"given":"Kathy","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin B.","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Basco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corie","family":"Gattis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabelle","family":"Friera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-4006","authenticated-orcid":false,"given":"Tobias","family":"Deuse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7696-6229","authenticated-orcid":false,"given":"Sonja","family":"Schrepfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcyt.2025.06.013_bib0001","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.013_bib0002","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.013_bib0003","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.jcyt.2025.06.013_bib0004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"DeStefano","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.05.018","article-title":"Efficacy and toxicity of CD19 chimeric antigen receptor T cell therapy for lymphoma in solid organ transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Yamshon","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.013_bib0006","article-title":"CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review","volume":"69","author":"Hernani","year":"2021","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.013_bib0007","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"issue":"26","key":"10.1016\/j.jcyt.2025.06.013_bib0008","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2025.06.013_bib0009","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.013_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.10595","article-title":"CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation","volume":"92","author":"Choquet","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.013_bib0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-023-02155-5","article-title":"Rituximab for posttransplant lymphoproliferative disorder \u2014 therapeutic, preemptive, or prophylactic?","volume":"59","author":"Storek","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.013_bib0012","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.16304","article-title":"Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder","volume":"189","author":"Jain","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.013_bib0013","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2014.298","article-title":"Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab","volume":"50","author":"Garcia-Cadenas","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jcyt.2025.06.013_bib0014","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbmt.2010.10.003","article-title":"Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation","volume":"17","author":"Coppoletta","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2025.06.013_bib0015","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1182\/blood.V99.12.4364","article-title":"Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation","volume":"99","author":"van Esser","year":"2002","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jcyt.2025.06.013_bib0016","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"Van Besien","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.jcyt.2025.06.013_bib0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcyt.2025.06.013_bib0018","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.013_bib0019","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-022-01907-z","article-title":"CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review","volume":"58","author":"Portuguese","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"10.1016\/j.jcyt.2025.06.013_bib0020","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jcyt.2025.06.013_bib0021","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2021-149786","article-title":"Real world evidence (RWE) of safety, efficacy, and outcomes of CD19 CAR-T therapy in 20 patients with solid organ transplant (SOT)-related post-transplant lymphoproliferative disorder (PTLD)","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"42","key":"10.1016\/j.jcyt.2025.06.013_bib0022","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1073\/pnas.1010560107","article-title":"Duration of antigen receptor signaling determines T-cell tolerance or activation","volume":"107","author":"Katzman","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.jcyt.2025.06.013_bib0023","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.4049\/jimmunol.0901459","article-title":"Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion","volume":"183","author":"Turner","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.013_bib0024","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.4049\/jimmunol.176.5.2730","article-title":"Prolonged TCR\/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin","volume":"176","author":"Colombetti","year":"2006","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jcyt.2025.06.013_bib0025","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.4049\/jimmunol.1003156","article-title":"OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling","volume":"186","author":"So","year":"2011","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.013_bib0026","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.4049\/jimmunol.0803986","article-title":"Naive CD4 T cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression","volume":"182","author":"Lin","year":"2009","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.06.013_bib0027","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.4049\/jimmunol.0803510","article-title":"Anergic T cells are metabolically anergic","volume":"183","author":"Zheng","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.013_bib0028","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1073\/pnas.92.5.1784","article-title":"Immunophilin FK506 binding protein associated with inositol 1,4,5-trisphosphate receptor modulates calcium flux","volume":"92","author":"Cameron","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5172","key":"10.1016\/j.jcyt.2025.06.013_bib0029","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.7518616","article-title":"Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12","volume":"265","author":"Wang","year":"1994","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jcyt.2025.06.013_bib0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2025.06.013_bib0031","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.jcyt.2025.06.013_bib0032","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.healun.2010.11.003","article-title":"P. Consensus Conference, Report from a consensus conference on antibody-mediated rejection in heart transplantation","volume":"30","author":"Kobashigawa","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.06.013_bib0033","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/TP.0000000000003095","article-title":"Recommended Treatment for Antibody-Mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group","volume":"104","author":"Schinstock","year":"2020","journal-title":"Transplantation"},{"issue":"18","key":"10.1016\/j.jcyt.2025.06.013_bib0034","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/bloodadvances.2020002435","article-title":"Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jcyt.2025.06.013_bib0035","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/s41467-017-01901-w","article-title":"Plasma cell survival in the absence of B cell memory","volume":"8","author":"Hammarlund","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jcyt.2025.06.013_bib0036","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/tan.15146","article-title":"Chimeric HLA antibody receptor T cells to target HLA-specific B cells in solid organ transplantation","volume":"102","author":"Gille","year":"2023","journal-title":"HLA"},{"issue":"95","key":"10.1016\/j.jcyt.2025.06.013_bib0037","doi-asserted-by":"crossref","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.jcyt.2025.06.013_bib0038","article-title":"Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies","volume":"4","author":"Zhang","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jcyt.2025.06.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104590","article-title":"Are we ready for CD19-targeted CAR T-cell therapies in MS?","volume":"70","author":"Giovannoni","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"10416","key":"10.1016\/j.jcyt.2025.06.013_bib0040","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925007637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:00:53Z","timestamp":1778943653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925007637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1465324925007637"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.013","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoimmune FK binding protein 12-knockout CD19 CAR T cells achieve deep tissue B-cell depletion and control Nalm6 tumors in immunosuppressed humanized mice","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}